


### Amendments to the Claims:


This listing of claims will replace all prior versions and listings of claims in the application.

### Listing of Claims:

- 1-5. (Cancelled)
6. (New) Derivatives of compounds Garcinol and Isogarcinol of



FORMULA I




FORMULA II


respectively, wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> of Garcinol and R<sub>4</sub> and R<sub>5</sub> of Isogarcinol are selected from a group comprising O-Methoxy, O-Ethoxy, O-Isopropoxy, O-

Allyloxy, O-Butoxy, O-t-Butoxy, O-Pentoxy, O-Hexyloxy, O-CH<sub>2</sub>-COOH, O-CO-CH<sub>2</sub>-CL, O-SO<sub>2</sub>-CH<sub>3</sub>, and O-CH<sub>2</sub>-CHOH-CH<sub>3</sub>.

7. (New) A process for preparation of derivatives of compound garcinol or Isogarcinol of formula I and II respectively, said process comprising step of reacting garcinol or Isogarcinol with halo compounds at temperature ranging between 30 – 40<sup>0</sup>C under alkaline conditions in presence of organic solvents, followed by purification to obtain the derivatives.
8. (New) A process for preparation as claimed in claim 7, wherein carrying the reaction in presence of alkaline hydroxides or alkaline carbonates.
9. (New) A process for preparation as claimed in claim 7, wherein the compounds are in equimolar concentration.
10. (New) A process for preparation as claimed in claim 7, wherein organic solvent is selected from a group comprising acetone, chloroform, MDC and EDC.
11. (New) A process for preparation as claimed in claim 7, wherein the derivatives are purified by column chromatography.
12. (New) A method of treating a disease condition selected from a group comprising cancer, asthma, cardiac hypertrophy, Acquired Immunodeficiency Syndrome (AIDS), Human Immunodeficiency Virus (HIV) in a subject in need thereof, wherein said method comprises step of administering pharmaceutically effective amount of derivatives of compounds Garcinol or Isogarcinol of



FORMULA I



FORMULA II

respectively, wherein R1, R2 and R3 of Garcinol and R4 and R5 of Isogarcinol are selected from a group comprising O-Methoxy, O-Ethoxy, O-Isopropoxy, O-Allyloxy, O-Butoxy, O-t-Butoxy, O-Pentoxy, O-Hexyloxy, O-CH<sub>2</sub>-COOH, O-CO-CH<sub>2</sub>-CL, O-SO<sub>2</sub>-CH<sub>3</sub>, and O-CH<sub>2</sub>-CHOH-CH<sub>3</sub> to the subject.

13. (New) A method as claimed in claim 12, wherein the derivatives are histone acetyl transferase (HAT) inhibitors.